Nature Medicine, Published online: 17 April 2026; doi:10.1038/d41591-026-00021-7
Three phase 1/2 trials show that direct editing of HBG1 and HBG2 promoters is a promising disease‑agnostic strategy for treating β‑hemoglobinopathies such as sickle-cell disease and β-thalassemia.
